---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-009115"
form_type: "8-K"
ticker: "CVRX"
cik: "0001235912"
company_name: "CVRx, Inc."
filed_at: "2025-02-04T23:59:59+00:00"
generated_at: "2026-05-27T03:19:50.187983+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CVRx Q4 2024 revenue $15.3M (+36% YoY); FY2025 revenue guidance $63-65M

## Summary
- Q4 2024 total revenue $15.3M, +36% YoY; U.S. HF revenue $14.3M, +41% YoY (457 units vs 330).
- FY2024 total revenue $51.3M, +31% YoY; net loss $60.0M ($2.65 per share) vs $41.2M in FY2023.
- Active implanting centers grew to 223 as of Dec 31, 2024, up 25% from 178 a year earlier.
- FY2025 guidance: total revenue $63-65M, gross margin 83-84%, operating expenses $100-104M.
- Cash and cash equivalents $105.9M as of Dec 31, 2024; net cash used in ops/investing $40.5M in FY2024.

## SEC filing metadata
- accession: 0001104659-25-009115
- form_type: 8-K
- ticker: CVRX
- cik: 0001235912
- company_name: CVRx, Inc.
- filed_at: 2025-02-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1235912/000110465925009115/0001104659-25-009115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1235912/000110465925009115/tm255369d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-009115
- JSON: https://secwatch.observer/filing/0001104659-25-009115.json
- Plain text: https://secwatch.observer/filing/0001104659-25-009115.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.